Shin Nippon Biomedical Laboratories Management
Management criteria checks 2/4
Shin Nippon Biomedical Laboratories' CEO is Ryoichi Nagata, appointed in Jan 1991, has a tenure of 33.83 years. directly owns 2.46% of the company’s shares, worth ¥1.27B. The average tenure of the management team and the board of directors is 2.4 years and 9.4 years respectively.
Key information
Ryoichi Nagata
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 33.8yrs |
| CEO ownership | 2.5% |
| Management average tenure | 2.4yrs |
| Board average tenure | 9.4yrs |
Recent management updates
Recent updates
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Sep 19
Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts
Aug 09Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding
Aug 06Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 26Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 12Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 21Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 10Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00
Mar 12Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Feb 27CEO
Ryoichi Nagata (66 yo)
33.8yrs
Tenure
JP¥144,061,000
Compensation
Dr. Ryoichi Nagata, M.D., Ph D., F.F.P.M., serves as President & Director of Satsuma Pharmaceuticals, Inc. since June 8, 2023 Also serves as it's Chief Executive Officer and Group Financial Officer since 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 33.8yrs | JP¥144.06m | 2.46% ¥ 1.3b | |
| Senior Executive Officer | 2.8yrs | no data | no data | |
| Managing Executive Officer | no data | no data | no data | |
| Senior MD of Corporate Development & Corporate Tax Administration and Director | 2.4yrs | no data | no data | |
| Senior Managing Executive Officer | no data | no data | no data | |
| Executive VP of Group Corporate Management & Global Business & Director | 20.4yrs | no data | 0.090% ¥ 46.4m | |
| Managing Executive Officer & GM of Fisheries Division | less than a year | no data | no data | |
| Senior MD | 1.8yrs | no data | no data | |
| Managing Executive Officer & President and Representative Director of SNBL Ina Research Center | no data | no data | no data | |
| Managing Executive Officer | less than a year | no data | no data | |
| Senior MD & Director | no data | no data | 0.043% ¥ 22.5m | |
| Executive VP | no data | no data | 40.33% ¥ 20.8b |
2.4yrs
Average Tenure
57yo
Average Age
Experienced Management: 2395's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 41.6yrs | JP¥144.06m | 2.46% ¥ 1.3b | |
| Senior MD of Corporate Development & Corporate Tax Administration and Director | 14.4yrs | no data | no data | |
| Senior Managing Executive Officer | no data | no data | no data | |
| Executive VP of Group Corporate Management & Global Business & Director | 21.9yrs | no data | 0.090% ¥ 46.4m | |
| Senior MD | 10.4yrs | no data | no data | |
| Senior MD & Director | 10.4yrs | no data | 0.043% ¥ 22.5m | |
| Executive VP | 4.4yrs | no data | 40.33% ¥ 20.8b | |
| Independent Outside Director | 9.4yrs | no data | 0.00096% ¥ 496.0k | |
| Independent Outside Director | 9.4yrs | no data | 0.00096% ¥ 496.0k | |
| Independent Outside Director | 4.4yrs | no data | 0.0098% ¥ 5.1m | |
| Independent Outside Director | 3.4yrs | no data | 0.0019% ¥ 992.0k | |
| Independent Outside Director | less than a year | no data | no data |
9.4yrs
Average Tenure
60yo
Average Age
Experienced Board: 2395's board of directors are considered experienced (9.4 years average tenure).